kgtoh/iStock via Getty Images Shares of Mustang Bio ( NASDAQ: MBIO ) rocketed 580% in afternoon trading Monday after the biotech company reported positive data from a Phase 1/2 trial for its CAR-T cell therapy MB-106 in the treatment of Waldenstrom macroglobulinemia, or WM, a type of non-Hodgkin lymphoma, or NHL. Mustang said the data showed an overall response rate of 90%, with one patient remaining in complete remission at 31 months. All ten patients enrolled in the study had been previously treated with BTKi therapies.
It added that outpatient administration of the product was allowed and found to be feasible, according to a statement . The company noted that there are currently no FDA approved CAR-T treatments for WM. The drug is being developed in collaboration with the Fred Hutch Cancer Center for B-cell NHL and chronic lymphocytic leukemia.
Mustang presented the data at the European Hematology Association 2024 Hybrid Congress. More on Mustang Bio Mustang Bio stock tumbles 27% amid news of mass layoffs Mustang Bio stock climbs 9% amid drug development update Seeking Alpha’s Quant Rating on Mustang Bio Historical earnings data for Mustang Bio Financial information for Mustang Bio.
